GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK’s Form 6-K announces EU approval of Blenrep (belantamab mafodotin) combinations for adults with relapsed/refractory multiple myeloma. The anti-BCMA ADC may now be given with bortezomib + dexamethasone after ≥1 prior therapy or with pomalidomide + dexamethasone after prior lenalidomide exposure.
Authorisation is driven by Phase III data: DREAMM-7 nearly tripled median PFS to 36.6 m vs 13.4 m for a daratumumab triplet (HR 0.41, p<0.00001) and cut death risk 42 % (HR 0.58). DREAMM-8 showed PFS not yet reached vs 12.7 m for control at 21.8 m follow-up. Ocular adverse events were manageable, leading to ≤9 % discontinuations. This becomes the sixth global approval for Blenrep combos and the first EU label enabling use from first relapse, expanding addressable patients (~50 k new EU cases/yr) ahead of pending US and China reviews. No financial figures were disclosed.
GSK continued its 2025 share-buyback programme. On 23 July 2025 the company repurchased 491,680 ordinary shares (≈0.012% of outstanding) at prices between 1,364.50 p and 1,374.50 p, yielding a volume-weighted average price of 1,369.42 p per share. All shares will be held in treasury.
Since the non-discretionary mandate with Merrill Lynch International commenced on 4 June 2025, 16,185,726 shares have been bought back. Treasury stock now totals 234,320,109 shares, representing 5.74 % of voting rights. The company’s share count (ex-treasury) stands at 4,081,064,171 shares, which is the new denominator for FCA transparency notifications.
The filing contains no earnings or strategic updates; it merely records routine execution of the authorised capital-return plan.
GSK plc filed a Form 6-K detailing activity under its ongoing share buyback. On 22 Jul 2025 the company repurchased 506,734 ordinary shares (nominal value 31⅔ p) via Merrill Lynch International at prices between 1,337.50 p and 1,359.00 p, generating a volume-weighted average price of 1,347.53 p. The stock will be held in treasury.
Since the non-discretionary agreement announced on 4 Jun 2025, GSK has bought back 15,694,046 shares. Post-transaction, treasury holdings rise to 233,828,429 shares (5.73 % of total voting rights), leaving 4,081,555,851 shares outstanding exclusive of treasury. The filing includes granular trade data for transparency and confirms the denominator for Disclosure Guidance & Transparency Rules reporting.
GSK plc disclosed that on 21 July 2025 it repurchased 504,228 ordinary shares (nominal 31¼ p) through Merrill Lynch International under its 4 June 2025 non-discretionary buy-back programme. Transaction prices ranged from 1,337p to 1,357p with a VWAP of 1,344.38p, representing a cash outlay of roughly £6.8 million. Since programme inception, 15,187,312 shares have been bought back.
All shares are held in treasury, increasing the treasury balance to 233,321,695 shares, now 5.72 % of total voting rights. Issued share capital (excluding treasury) stands at 4,082,062,585 shares, which becomes the denominator for FCA DTR calculations. No earnings, guidance or other financial data were included.
On 18 Jul 2025, GSK plc bought back 505,771 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its previously announced non-discretionary buy-back programme.
The shares were purchased between 1,319.0 p and 1,360.5 p, with a volume-weighted average price of 1,344.42 p. Since the programme commenced on 4 Jun 2025, GSK has repurchased 14,683,084 shares.
Following this latest transaction, the company now holds 232,817,467 shares in treasury, representing 5.70 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,082,566,813, which investors should use as the denominator when assessing disclosure thresholds under the FCA’s DTR rules.
The filing contains no new earnings or guidance; it solely updates the market on the progress of GSK’s authorised share-repurchase programme.
On 15 Jul 2025, GSK plc repurchased 487,387 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its on-market buy-back. The shares were bought at 1,401.50-1,493.50 p, giving a volume-weighted average price of 1,423.89 p and an estimated cash cost of £6.9 million.
Since the non-discretionary programme began on 4 Jun 2025, GSK has acquired 13,210,173 shares. The company now holds 231,344,556 shares in treasury, equivalent to 5.66 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,084,039,501, which is the denominator investors should use for disclosure calculations under the FCA’s DTR rules.